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Like its enteric counterpart, aspartate transcarbamoylase (ATCase) from 
Pseudomonas putida is a dodecamer of two different polypeptides. Unlike the enterics, 
the Pseudomonas ATCase lacks regulatory polypeptides but employs instead  inactive 
dihydroorotases for an active dodecamer. Previous work showed that PyrB contains not 
only the active site but also the effector binding sites for ATP, UTP and CTP at its N-
terminus. In this work, 11 amino acids were deleted from the N-terminus of PyrB and the 
ATCase with the truncated protein was expressed in E. coli pyrB- and purified. The wild 
type enzyme was similarly treated. Velocity-substrate plots without effectors gave 
Michaelis-Menten kinetics in all cases. Deleting 11 amino acids did not affect 
dodecameric assembly but altered effector responses. When carbamoylphosphate was 
varied, the mutant enzyme was inhibited by UTP while the wild type enzyme was 
activated 2-fold. When the aspartate was varied, CTP had no effect on the mutant enzyme 
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Pseudomonads are famous both for their omnivorous nutritional and metabolic 
versatility, and also for their wide environmental distribution. They play very important 
roles in chemical transformations of organic materials (10). Also, Pseudomonas species 
have achieved research prominence in microbiology in particular P. aeruginosa as it is 
associated with human infection, and because of its biochemical diversity. Pseudomonads 
also have strong relations with the environment because these bacteria interact with 
plants and play key roles in biodegradation of natural and man-made accumulation of 
toxic chemicals. Pseudomonads are a major group of chemoorganotrophic aerobic Gram-
negative rods that lack a fermentative metabolism (7). 
The genus Pseudomonas comprises a vast diverse group of bacteria. 
Pseudomonas putida, the subject of this thesis, is one of the fluorescent pseudomonads 
and can be found in a variety of natural environments. P. putida is a Gram-negative, 
aerobic, fluorescent pseudomonad, which grows optimally at around 30ºC. Like other 
pseudomonads, P. putida thrives in moist environments. Its isolation from clinical 
specimens is an unusual event and is considered to have uncertain pathogenic 
significance. In immunocompromised patients, P. putida has been found to cause 
septicemia and septic arthritis (2,20). 
Pyrimidine Pathway 
 The pyrimidine biosynthetic pathway is important for all organisms because it 
provides the building blocks namely UTP and CTP for ribonucleic acid (RNA), and 
dCTP and dTTP for deoxyribonucleic acid (DNA). There are two main pathways to 
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synthesize the RNA and DNA precursors. The first one is the pyrimidine biosynthetic 
pathway and the second is the pyrimidine salvage pathway. The former is a series of nine 
reactions, which lead to the formation of uridine-5-triphosphate (UTP) and cytidine-5-
triphosphate (CTP). The salvage pathway is required for the recycling of UMP and CMP, 
the degradation products of mRNA turnover. The salvage pathway is also required for the 
feeding of exogenous nucleosides and bases to mutants of the biosynthetic pathway. At 
any time during the growth phase, the biosynthetic and salvage pathways each contribute 
50% of the RNA synthesized. Thus, the salvage pathway maintains a metabolic balance 
in the cell. 
Almost all organisms can make the purine and pyrimidine nucleotides by the de 
novo biosynthetic pathways. Pyrimidines are not synthesized as nucleotide derivatives. 
Instead, the pyrimidine ring system is completed before a ribose-5-P moiety is attached. 
Only two precursors, carbamoylphosphate and aspartate, contribute atoms to the six-
membered  pyrimidine ring. 
The de novo pathway for pyrimidine biosynthesis is universal and virtually 
identical in all organisms (figure 1). Even though the sequence of events is similar in all 
organisms, the regulation of these events differs from one organism to another. The     
pathway, in general, is controlled at the level of enzyme activity by feedback inhibition 
and activation, and at the level of enzyme synthesis by repression and attenuation. In E. 
coli K-12, six consecutive, unlinked genes and small operons designated as carAB, pyrBI, 
pyrC, pyrD, pyrE, and pyrF encode the six enzymes of the pyrimidine pathway to UMP. 
This pathway is responsible for the synthesis of UMP, which is a precursor of all 
pyrimidine nucleotides. As mentioned above the pathway also provides the precursors for 
 3
deoxyribonucleotide biosynthesis, leading to the formation of dCTP and ultimately, dTTP 
(27). 
 
Figure 1. The de novo pyrimidine biosynthetic pathway to UMP. 
The first enzyme in the de novo pathway is encoded by the operon carAB. This 
enzyme is called carbamoylphosphate synthetase (CPSase). In the enteric bacteria it 
functions in two biosynthetic pathways those of pyrimidines and arginine. Synthesis of 
this enzyme is controlled by cumulative repression by both arginine and a cytidine 
nucleotide, both of which are end products of their respective pathways (24, 28). 
 The enzyme that catalyzes the first reaction unique to pyrimidine biosynthesis is 
encoded by the second operon (pyrBI). This enzyme is designated aspartate 
transcarbamoylase, and it is involved in the carbamoylation of the amino group of 
carbamoylphosphate to produce carbamoylaspartate. This is the first committed step in 
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the pyrimidine pathway, which converts the precursors carbamoylphosphate and aspartate 
into carbamoylaspartate (CAA) and Pi .  
  ATCase is a highly conserved feature of the pathway; variations have been 
reported in both its regulation and size. In 1969, these variations led to a classification 
system proposed by Bethell & Jones (4). 
The synthesis of ATCase is controlled by attenuation and its activity is controlled 
by allosteric inhibition by CTP and activation by ATP (12). CAA is converted next to 
dihydroorotate by the enzyme dihydroorotase (DHOase). This enzyme is encoded by 
pyrC gene. Next, the product of this reaction is oxidized to orotate. This step is catalyzed 
by the enzyme dihydroorotate dehydrogenase, which is encoded by the pyrD gene. Then, 
orotate combines with the phosphoribosyl group of 5-phosphoribosyl-1-pyrophosphate 
(PRPP) to form orotidine-5-monophosphate (OMP), and this is the first pyrimidine 
nucleotide produced (11). The enzyme that  catalyzes this step is orotate 
phosphoribosyltransferase, which is encoded by pyrE gene. OMP is then decarboxylated 
to uridine-5-monophosphate (UMP). This step is catalyzed by OMP decarboxylase, 
which is encoded by the pyrF gene. UMP is phosphorylated to UDP using ATP as the 
source of phosphate. This enzyme, UMP kinase, is highly specific for UMP.  Next, 
uridine-5- diphosphate is phosphorylated to UTP, again using ATP, by the enzyme 
nucleoside diphosphokinase. The last step in this pathway is the production of CTP from 
UTP. This step is catalyzed by the enzyme CTP synthetase, which is encoded by pyrG 
gene. Glutamine serves as the amino donor in this reaction(26). 
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Aspartate Transcarbamoylase (ATCase) 
Bacterial ATCases have been divided into three classes based on molecular 
masses of the holoenzyme (4) (Fig.2). Class A ATCases are dodecameric (Fig 4) with a 
molecular mass of approximately 480 kDa. This class of ATCases is the largest and is 
sensitive to allosteric effectors. The genes for class A enzymes were originally cloned 
and sequenced from Pseudomonas aeruginosa (39) and P. putida (33). 
 
Figure 2.  The three classes of bacterial ATCases. 
The Pseudomonas ATCase belongs to class A ATCase (Fig 3). Members of this 
class have large ATCases with a molecular mass of 484 kDa. In Pseudomonas ATCase, 
unlike class B, both catalytic and regulatory sites reside in the 34 kDa polypeptides (9, 
21, 22). The nucleotide sequence of the P. putida ATCase has been determined. The P. 
putida genes are arranged in an operon with three open reading frames (ORFs), a 5’ ORF 
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corresponding to the pyrR gene (23), the middle ORF corresponding  to the pyrB gene 
and a downstream ORF with significant sequence similarity to the pyrC gene encoding 
dihydroorotase (DHOase). In P. putida, the pyrB gene is 1005bp and is translated to 334 
amino acids encoding polypeptide of 34.5 kDa (33). The pyrC gene with 30% sequence 
similarity to the E. coli DHOase, has 1275bp encoding 424 amino acids giving a 
polypeptide of 44.2 kDa. Because this polypeptide is catalytically inactive, it is 
designated PyrC’ (DHOase-like) (33). The PyrC’ polypeptides are required for the 
activity of the holoenzyme. It was expected that the PyrC’ functioned as a source of 
nucleotide binding sites but Bergh & Evans, 1993 and Schurr et al., 1995 showed that the 
nucleotide binding sites were located on the PyrB polypeptides. 
 
Figure 3.  The pyrimidine pathway in Pseudomonas.  Heavy lines denote salvage 
pathways. 
The Pseudomonas holoenzyme is inhibited by all triphosphates, pyrophosphate, 
and orthophosphate at limiting concentration of carbamoylphosphate. The ATCase of 
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Pseudomonas was thought to be a dimer (1) until Schurr et al. 1995 provided the DNA 
sequence. Adair and Jones (1972) suggested that the ATCase from P. fluorescens was 
composed of two identical subunits, each with a molecular weight of 180 kDa. Recent 
studies on the ATCase of P. putida and P. aeruginosa show that there is no separate 
regulatory gene, but that the first gene in the sequence (pyrB) solely encodes ATCase, 
with shared catalytic and regulatory activities. The second gene (pyrC’) encodes an 
inactive DHOase (Schurr Ph.D. Dissertation, UNT, 1992). The gene for the active 
DHOase was cloned and sequenced by Dayna Brichta from P. aeruginosa.  Class B 
enzymes are dodecamers like those of class A ATCases, but they have a smaller 
molecular mass. Class B ATCases have an average molecular mass of 310 kDa .  
E. coli ATCase (Fig 4) is a typical class B enzyme. It consists of six copies of two 
polypeptides, catalytic chains of 34 kDa and regulatory chains of 17 kDa for an overall 
structure 2c3:3r2 (16).  
The E. coli ATCase has been the most studied (Fig 5). The catalytic activity of 
ATCase is dependent on the formation of an active site from half-sites and separate 
subunits (17, 31). The catalytic polypeptide is composed of two domains, the polar 
domain, at the N-terminus, binds carbamoyl phosphate and the equatorial domain at  C-
terminus, binds aspartate. Each active enzyme is a trimeric protein containing three active 
sites. E. coli and the enteric bacteria contain a second polypeptide, with regulatory 
properties only, which efficiently binds nucleotide effectors (ATP, and CTP) when 
regulating enzymatic activity. In these bacteria, the pyrBI genes lie beside each other and 
are expressed coordinately. The catalytic polypeptides are encoded by the pyrB gene and 
the regulatory polypeptides are encoded by the pyrI gene. These polypeptide chains 
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together form a dodecamer, containing two trimeric catalytic subunits and three dimeric 
regulatory subunits (2c3 : 3r2). 
 
Figure 4.  Synthesis of aspartate transcarbamoylase from E. coli and Pseudomonas.  In E. 
coli, pyrB and pyrI are separated by 15bp while in Pseudomonas the pyrB and pyrC’ 
genes overlap by 4bp. The pyrB gene encodes the catalytic ATCase in both cases while 
pyrI encodes a regulatory polypeptide in E. coli and pyrC’ an inactive DHOase in 
Pseudomonas that is required for enzyme activity. 
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Figure 5.  The pyrimidine biosynthetic and salvage pathways in E. coli. 
In E. coli , the amino acid sequence of the two polypeptide chains is known. The catalytic 
region consists of two tryptophan residues besides a cysteine near the catalytic site of the 
enzyme (13). A similar site is found in the Pseudomonas enzyme (32). 
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Regulation of ATCase in E. coli  
 ATCase regulation in E. coli is by allosteric inhibition and activation. The enzyme 
is allosterically inhibited by CTP and activated by ATP. The binding of ATP and CTP to 
the regulatory sites was shown to be anti-cooperative, which means that they compete for 
a single site on the regulatory subunit (37). A primary- secondary effects model has been 
used to interpret the heterotropic interaction involved in the binding of these effectors to 
the enzyme. The nucleotides act by changing the affinity of the catalytic site for aspartate 
by local conformational changes. Therefore, this model reveals the fact that ATP reverses 
the effect of CTP and the opposite is also true (38). So, when ATP binds to the regulatory 
site of the enzyme, it promotes a local conformational change, which increases the 
affinity for aspartate to the catalytic site of the enzyme, this is called the primary effect. 
However, the secondary effect occurs in the presence of aspartate. The conformational 
changes that made by ATP increase the level of saturation of the catalytic sites by 
aspartate. These changes shift the T and R equilibrium towards the R state.  On the other 
hand, CTP, when it binds to the regulatory site of the enzyme, promotes a local 
conformational change that decreases the affinity of aspartate for the catalytic site. Here, 
and in the presence of aspartate, these conformational changes decrease the saturation of 
the catalytic sites for this substrate and shift the T and R equilibrium toward the T form.    
Class C enzymes are found in all Gram-positive bacteria. This class of ATCase is 
the smallest with a molecular mass of about 100kDa. Also, this class is insensitive to 
allosteric effectors. Bacillus subtilis ATCase is a trimer composed of three-33.5kDa 
polypeptides with a tertiary structure very similar to the E. coli catalytic subunits (36). 
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The class C ATCase consists of three catalytic polypeptide chains with a molecular mass 
of 102 kDa. 
ATCase is found to exist in two different forms, which are called R and T states 
(Fig 6). A taut conformation (T-state) has a low affinity for aspartate, while the relaxed 
conformation (R-state) has a strong affinity for aspartate. The transitions from T state to 
R state involve the simultaneous breaking of interface localized bonds, and formation of 
the others at different interface sites (16, 18). 
 
Figure 6.  Schematic representation of the T to R transition of the E. coli ATCase.  C = 
catalytic chain, r = regulatory chain. 
In mammals, ATCase activity is associated with a single CAD polypeptide with 
three domains for CPSase, ATCase and DHOase, which catalyze the first three steps in 
pyrimidine biosynthesis (34). The mammalian ATCase domain is an unregulated trimer 
composed of 34kDa subunits (35). The similarity in sequence among the catalytic 
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polypeptides of E. coli ATCase, B. subtilis ATCase and eukaryotic ATCase domains 
suggests a highly conserved structure. 
Protein Purification 
Chromatography 
  Chromatography as well as all other protein purification methods takes advantage 
of relative differences between the chemical and physical properties of amino acids. 
Amino acids can be separated according to their solvent affinity or their electrical charge. 
In the partition method, the protein is allowed or forced to flow through a medium 
consisting of two phases-solid-liquid, liquid-liquid, and gas-liquid. In general due to the 
acid-base groups of amino acids, protein solubility depends on salts concentration, the 
polarity of the solvent, the pH, and the temperature. 
  The power of chromatography derives from the continuous nature of the 
separation process. At the end, the separated components are collected and submitted to 
further analysis. The various chromatography methods are classified according to their 
mobile and stationary phases. For example, in liquid-liquid chromatography there are 
immiscible liquids, one of which is bound to an inert solid support. Chromatographic 
methods are further classified according to the nature of the dominant interaction between 
the stationary phase and the substances being separated. For example, if the retarding 
force is ionic in character, the separation technique is referred to as ion chromatography, 
whereas if it is a result of adsorption of the solutes onto a solid stationary phase, it is 
known as adsorption chromatography. 
A cell contains huge numbers of different categories of components, many of 
which closely resemble one another in their various properties. Therefore, the isolation 
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procedures for most biological substances use a number of independent chromatographic 
steps in order to purify the substance of interest according to several criteria. In this 
research, different chromatographic techniques are used in order to purify ATCase. 
The first technique is Ion Exchange Chromatography. In this techniques, Ions that 
are electrostatically bound to an insoluble and chemically inert matrix are reversibly 
replaced by ions in solution (Fig 7). In the process, the solutes in the liquid phase, usually 
water, are passed through columns filled with a porous solid phase, usually a bed of 
synthetic resin particles, containing charged groups (Fig 8). Negatively charged resin 
attracts positively charged species whereas positively charged resin attracts negatively 
charged species (11).  
 
Figure 7.  Mode of action of a cation exchange column. 
The second chromatography method used in this research is Hydrophobic 
Exchange Chromatography. Sepharose is a bead-formed gel prepared from agarose. In its 
natural state agarose occurs as part of the complex mixture of charged and neutral 
polysaccharides referred to as agar. The agarose used to make Sepharose is obtained by a 
purification process, which removes the charged polysaccharides to give a gel with only a 
very small number of residual charged groups. Therefore, hydrophobic interaction 
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chromatography uses the hydrophobic nature of proteins in purifying them.  Before 
running the chromatography, the column is prepared and regenerated as follows: the  
 
Figure 8.  Cation and anion exchange resins commonly used for biochemical separation. 
agarose beads are washed twice with 50% ethanol, once with n-butanol and again twice 
with 50% ethanol and then with plenty of water. The column is then packed and 
equilibrated with high buffer. After regeneration of the column the ATCase is eluted.  
Hydrophobic groups are covalently linked to the phenyl Sepharose matrix. 
Therefore, in the presence of high salt concentration, proteins bind to the phenyl groups 
by virtue of hydrophobic interaction. Proteins in a mixture can be differentially eluted 
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from the phenyl group by lowering the salt concentration or by adding solvent such as 
ethylene glycol to the elution fluid. Once the elution is finished the hydrophobic 
interaction chromatography gel can be reused several times depending on the quality of 
the buffer. 
Enzyme Kinetics 
 The study of enzyme kinetics is very important in the field of molecular biology. 
From this study, the maximum reaction velocity that the enzyme attains can be 
determined. Its binding affinities for substrates and inhibitors can also be determined. 
Therefore, this information can be used to control and manipulate the course of metabolic 
events. 
 In 1913, Michaelis and Menten proposed a general theory of enzyme action. This 
theory was based on the assumption that the enzyme and its substrate associate reversibly 
to form an enzyme-substrate complex. There are some factors such as pH that can 
decrease or increase the enzyme activity. In general, enzymes are active only over a 
limited pH range and most have a particular pH at which their catalytic activity is 
optimal. The effects of pH on the enzyme activity may be due to effects on Km or Vmax or 
both. The other factor that can affect the enzyme activity is the temperature. In general, 
the rates of enzyme-catalyzed reaction are increased with increasing temperature. 
However, temperature above 50°C decreases the activity of most enzymes. 
Enzyme Inhibition 
Inhibitors of enzymes can be classified into two types. The first type is called 
reversible inhibitors. This type of inhibitor interacts with the enzyme in a noncovalent 
association. The other type is called irreversible inhibitors in contrast with the first type. 
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This type causes a stable and covalent alteration in the enzyme. The reversible inhibitors 
are of two kinds namely competitive and noncompetitive inhibitors. In the case of the 
competitive inhibitors, the substrate and the inhibitor compete for the same binding site 
on the enzyme, whereas the noncompetitive inhibitors are not binding to the same site as 
the substrate does. 
The purpose of this study was to compare the effector response between the wild 
type Pseudomonas putida ATCase and a mutant ATCase lacking 11 amino acids at the 
N-terminus. The effectors used in this study were ATP, CTP, and UTP. After the protein 
(ATCase) was purified from both the wild type and the mutant type, the ATCase assay 
was done on each type. In this ATCase assay, ATP, CTP, and UTP were used as effectors 
since each had been shown to inhibit the enzyme by previous workers (32).  
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MATERIALS AND METHODS 
Chemicals 
Ampicillin monosodium salt, agarose, dibasic potassium phosphate, monobasic 
potassium phosphate, ammonium sulfate, sodium citrate, magnesium sulfate, thiamine, 
dextrose, Tris, chloride, ammonium persulfate, sodium dodecyl sulfate, and EDTA 
disodium salt were all provided by Fisher Scientific Co. Luria-Bertani medium, sodium 
chloride, potassium chloride, bromophenol blue, and granulated agar were provided by 
Difco laboratories. Aspartate, carbamylphosphate, isopropyl-B-thio-galactopyranoside 
(IPTG), bisacrylamide, acrylamide, and calcium chloride dihydrate were provided by 
Sigma Chemical Company. Glycerol and ethanol were provided by EM Science. Type II 
H2O was generated by a Barnstead NANOpure ultrapure water system. All type II H2O 
was then autoclaved. Also, different chemical materials have been used.Antipyrine and 
monoxime are required for ATCase assay. Effectors, ATP, CTP, and UTP were used in 
this study at final concentration of 2mM. 
Media and Bacterial Strains 
Luria-Bertani (LB) enriched medium (3) was used for strains and plasmid 
constructions with the following antibiotics as required : ampicillin, 100 µg/mL (E. coli); 
kanamycin, 50 µg/mL (E. coli). 
The E. coli minimal medium (25) contained the following (grams per liter of 
distilled/deionized water): K2HPO4, 10.5; KH2PO4, 4.5; (NH4)2SO4, 1.0; Na3 citrate, 0.5. 
This solution was autoclaved and cooled to 50ºC before adding glucose (10mL of 20% 
solution), MgSO4 (1mL of 1M), thiamine (5mL of 0.4% solution) and arginine 
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(50µg/mL). The glucose was used as a carbon source. All E. coli strains were grown at 
37ºC. All strains and  plasmids used in this study are listed in Table1 . 
Preparation of Competent Cells for Transformation 
A single colony was inoculated into 50 mL of L-Broth and incubated, with 
shaking at 37°C until OD600 reached between 0.2 and 0.4 OD units. The cells were then 
harvested by centrifugation at 1300 xg for 15 min. Then the pellet was resuspended in 
20mL of cold 0.1 M CaCl2 and then incubated at 0°C for 20 min, and harvested by 
centrifugation at 1300 xg for 15 min. Next, CaCl2 was used to resuspend the pellet. After 
24 hours, 50% glycerol was added to the cells giving a final concentration of 15% 
glycerol, which were rendered competent. 
Genetic Manipulation 
Transformation of DNA in E. coli TB2 was carried out by the following method 
(14): 
3µL (600ng) from each plasmid used in the transformation was added to a 1.5mL 
microfuge tube. Then 200µL from the competent cell was added to the same tube, and 
placed on ice for 10 min. Then it was incubated in water bath (42°C) for 2 min. 1mL of 
LB broth medium was added to the tube and incubated for 45min in gyrorotary shaker at 
37°C and 250 rpm. This incubation allows the cells to recover. Finally the transformed 
cells were spread onto plates of LB agar supplemented with ampicillin and kanamycin 
and then were grown on E. coli minimal medium plates with arginine , ampicillin and 
kanamycin and the growth was monitored.  
In this study two transformations were done. The first one included pKPB-11 (–
11aa PyrB) (Fig 9) and pDBPC’ ( PyrC’) (Fig 10), this is for the mutant type (Fig 12). 
 19
The second transformation included pAKB10 ( PyrB WT) (Fig 11) and pDBPC’ (PyrC’), 
and this is for the wild type (Fig 12). 
Figure 9.  P. putida pyrB-11 insert in the expression vector pKK223-3. 
 
Figure 10.  P. putida pyrC'' in pK184. 
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Figure 11.  P putida pyrB in pUC19. 
Figure 12.  P. putida ATCase made in trans from both wild and mutant types. 
 
Co-transform into E. coli
TB2 pyrB- and look for 
pyrimidine prototrophy 
Wild type P. putida ATCase
made in trans. 
Mutant P. putida ATCase
made in trans. 
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From the plates that have the transformed cells, many colonies were inoculated in 
E.coli minimal medium plates using toothpick process. Those plates were supplied with 
the chemicals they need and incubated at 30°C overnight. Then one colony was 
inoculated in 50mL E. coli minimal medium. 
For 50mL of E.coli minimal medium, 500µL of 20% glucose, 250µL of 0.4% 
thiamine, 50µL of 1.0M of MgSO4, 250µL of 2.54% arginine, 50µL of Amp100, and 
50µL of Kan50 were added. This 50mL was incubated at 30°C and the growth noted; 
10mL from this culture was inoculated in one liter of E. coli minimal medium (4L from 
the medium was used). These cultures were incubated at 30°C for about 16 hours. 
Purification of P. putida Wild Type ATCase and Mutant ATCase  
The P. putida ATCase was purified in E. coli TB2. The enzyme was purified from 
4 liters of culture by the method of Adair and Jones (1).  
The cells were incubated at 30°C for about 16 hours. Then, the cells were broken 
by using the French pressure cell (French Press). This machine achieves cell lysis by 
placing the sample under high pressure followed by a sudden release to atmospheric 
pressure. The rapid change in pressure causes cells to burst. This procedure works very 
well for moderate volumes (10-30mL), but becomes technically difficult with smaller 
volumes . After breakage, the cells were resuspended in ATCase buffer. The broken cells 
were transferred to a centrifuge tube (using SA600), and the centrifugation was done at 
10700 xg for 1 hour. This centrifugation precipitates the cell wall and the cell membrane 
fractions. Then 2% streptomycin cut was done on the supernatant. The solution was 
centrifuged at 10700 xg for 30 min. A 30% ammonium sulphate cut was carried out after 
this centrifugation. Then a 50% ammonium sulphate cut was completed. The 
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centrifugation done at 10700 xg for 30 min as before. The pellet was resuspended in 1mL 
ATCase buffer. 
Dialysis 
Dialysis is a method for concentrating protein solution by dialyzing against a 
hygroscopic environment. The protocol for this process is as following: 
1- Make two tight knots at one of the tubing. 
2- Using a pipet or funnel, deliver a protein solution into the dialysis tubing. 
3- Tie a double knot at the end of the tubing and place the closed dialysis bag in 
>10 volume of dialysis buffer. The buffer should be stirred gently with a 
magnetic stir bar to improve solute exchange. Equilibrium occurs after several 
hours of dialysis, and the dialysis buffer may have to be changed several times 
until certain buffer components are sufficiently diluted.    
An ionic exchange column was used with DEAE Sepharose as a matrix.  Then, all 
other ATCasees were purified using a phenyl sepharose Hydrophobic Interaction Column 
(HIC) following ammonium sulphate precipitation and the proteins were eluted with a 
predetermined salt concentration. Sepharose is a bead-formed gel prepared from agarose. 
Agarose, in its natural state, occurs as part of the complex mixure of charged and neutral 
polysaccharides referred to as agar. Hydrophobic interaction chromatography uses the 
hydrophobic nature of proteins in purifying them. Before running the chromatography, 
the column is packed and equilibrated with high buffer. Here, hydrophobic groups are 
covalently linked to the phenyl sepharose matrix. Therefore, in the presence of high salt 
concentration of ammonium sulphate, proteins bind to the phenyl groups by virtue of 
hydrophobic interaction. ATCase, the subject of this study, was eluted when the salt 
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concentration was at 0M, which is the lowest concentration. In other words, it is eluted 
with the ATCase buffer. Then the ATCase assay was performed on purified proteins. 
Protein concentration was determined by the method of Bradford (6). 
Aspartate Transcarbamoylase Assays 
The ATCase assay was the same for both the wild type and the mutant type and is 
routinely carried out in our lab. The following reagent were mixed in the following 
amounts: 54µL ddH2O, 28µL tri-buffer (50mM MES, 100mM diethanolamine, and 
51mM N-ethylmorpholine, pH 9.5), and 35µL 20X aspartate (200mM aspartate). 87µL of 
this mixture was distributed into the microtiter wells. Then, to these wells 3µL from the 
enzyme was added. The reaction was initiated by adding 10µL of carbamoylphosphate to 
each well. The samples were incubated 15 minutes at 30°C. After incubating, the reaction 
was stopped by adding 100µL of stop mix reagent (2 parts antipyrine and 1 part 
monoxime, combined just before use). The samples were then incubated in the presence 
of light for about 2 hours at 60°C. the samples were then read on the Molecular Devices 
Company microplate reader. The ATCase was assayed under two sets of conditions, 
under varying aspartate concentration and under varying carbamoylphosphate 
concentration. 
Aspartate concentrations ranged from 0.1mM aspartate to 20mM aspartate while the 
carbamoylphosphate concentrations ranged from 0.1mM CP to 3mM CP.      
The ATCase activity was assayed by measuring CAA formation at 30°C with 
modifications using the color development procedure (12, 29). The nucleotide effectors 
that have been used in this study include: 20mM ATP, 20mM CTP, and 20mM UTP. In 
the microtiter wells, the first set was run without any effector, the second set included 
 24
ATP, the third included CTP, and the last one included UTP. The amount that has been 
added from the effectors (10µl) was adjusted with H2O. 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
This method separates proteins based primarily on their molecular weights. SDS 
binds along the polypeptide chain, and the length of the reduced SDS-protein complex is 
proportional to its molecular weight. The separating gel was prepared by degassing a 
mixture containing 5mL of 30% acrylamide/ 0.8% bisacrylamide, 2.5mL of 4X Tris-
HCl/SDS pH 8.8.then, 0.02g of 10% ammonium persulfate was added. This solution was 
then mixed with 5µL of TEMED. Once the TEMED was added to the mixture, the 
separating gel was added to the apparatus with a Pasteur pipet to a height of 11cm. 
Another Pasteur pipet was used to cover the top of the gel with a 1cm layer of 
H2O-saturated isobutyl alcohol. The gel was allowed to polymerize for one hour at room 
temperature. While the gel was polymerizing, a stacking gel was  made by combining 
0.67mL of 30% acrylamide/0.8% bisacrylamide, 1mL of 4X Tris-HCl pH 6.8, and 2.3mL 
ddH2O. the mixture was degassed for 15 minutes and 0.02g of 10% ammonium persulfate 
and 5µL of TEMED were added. Then, the solution was mixed by swirling. The alcohol 
was then poured off of the gel. The stacking gel solution was then added and a comb 
inserted. The gel was allowed to polymerize for 45 minutes. 
After polymerization, the samples were heated for about 3 minutes at 100°C in a 
sealed microcentrifuge tube. The comb was then removed from the gel and the wells 
were rinsed with 1X electrophoresis buffer. The samples were then loaded into the wells, 
as were the standards. 1X electrophoresis buffer was then used to fill in all the empty 
wells and to fill the chamber to the upper electrode.  Then, the chamber was sealed and 
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connected to the power supply and run at 100 volts until the bromophenol blue tracking 
dye reached the bottom of the separating gel (approximately 1 hour). The gel was then 
stained with coomasie blue for about 24 hours. 
Nondenaturing Gel Electrophoresis (Native Gel Electrophoresis) 
This gel separates proteins based on their size and charge properties. This method 
is able to separate molecules which differ by a single unit charge. The separating gel was 
prepared by mixing 3.3mL of 30% acrylamide/0.8% bis-acrylamide, 2.5mL of 4X Tris-Cl 
pH 8.8, and 4.2mL ddH2O. The mixture was then mixed with 0.02g of 10% ammonium 
persulfate and 5µL of TEMED. Directly after the TEMED was added, the separating gel 
solution was added to the apparatus with a Pasteur pipet. A 1 cm gap was left at the top of 
the gel plates for pouring the stacking gel later. Then, another pipet was used to cover the 
top of the gel with a 1cm of isobutyl alcohol. Gel was allowed to polymerize for about 45 
minutes at room temperature. Then, the stacking gel was made by combining 0.67mL of 
30% acrylamide/0.8% bis-acrylamide, 1mL of 0.5M Tris pH 6.8, and 2.3mL of ddH2O. 
then, 0.02g of 10% ammonium persulfate and 5µL of TEMED were added to the mixture. 
The alcohol was then removed and the stacking gel solution was added and the comb was 
inserted. The gel was allowed to polymerize for about 45 minutes. The comb was then 
removed from the gel and the wells were cleaned. The samples were then loaded into the 
wells. 1X electrophoresis buffer was then used to fill the chamber to the upper electrode. 
The buffer contained 3.02 g of Tris, 14.4 g of glycine in 1 liter of ddH2O at pH 8.3 was 
used as the electrophoresis buffer. The chamber was sealed and connected to the power 
supply and electrophoresed at 100 volts until the dye reached the bottom of the separating 
gel. The gel was then stained to show only ATCase activity. 
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The ATCase activity can be detected directly on the gel by activity staining, a 
method developed by Bothwell (5) and further modified by Kedzie (19). The gel was 
placed in ice-cold 50mM histidine (free base), pH7.0, for 5 minutes to which 5mL of 
1.0M aspartate and 10mL of 0.1M carbamoylphosphate were added and allowed to react 
for 20 minutes. The gel was rinsed three times with ice-cold distilled water to remove 
reactants. Each wash should be done for 5-10 minutes in order to avoid a dark 
background after finishing the staining process. The enzymatically released Pi trapped in 
the gel was precipitated by a reaction with 3 mM lead nitrate in ice-cold 50 mM histidine, 
pH 7.0, for 10 minutes. The soluble lead ions were removed with three changes of ice-
cold water. If the protein samples contained ATCase, the ATCase band can be visualized 
as the white band after this step. The gel was then stained with 1% sodium sulfide, which 
converted the white lead phosphate precipitate into dark lead sulfide bands. 
Table 1.  Strains and Plasmids 
Strain(*) or Plasmid (‡) Description or Relevant Phenotype Source 
TB2* (E. coli) ∆ pyrBI, argI, argF W.D.  Roof 
PKPB-11‡  -11aa PyrB (P. putida) in pKK223-3 A. P. Kumar 
pK184‡ p15a replicon, Kanr New England Biolabs 
pAKB10‡ pyrB (P. putida) in pUC19 A. P. Kumar 








Transformation of Plasmid pAKB10 (P. putida pyrB gene) and  
pDBPC’ (P. putida pyrC’ gene) into E. coli TB2 
 E. coli TB2 strain was used in the transformation in this study. This strain is 
devoid of ATCase activity due to deletion of the pyrBI region. When the E. coli TB2 
strain was co-transformed with both plasmids, one carrying a functional pyrB and the 
other carrying pyrC’, the strain grew in the absence of uracil. The transformants were 
first plated on LB agar containing ampicillin and kanamycin. Then the transformants 
were grown in E. coli minimal medium with glucose as a carbon source as described in 
Materials and Methods. If the transformed plasmids encoded an active ATCase, then 
these transformed cells should grow in the absence of uracil. Because the transformed 
cells grew in the E. coli minimal medium, then an active ATCase was encoded and 
complemented the E. coli TB2 strain. This ATCase was purified (as described in 
Materials and Methods) and used for further study. 
Transformation of Plasmids pKPB-11 (P. putida –11 aa pyrB gene) and  
pDBPC’ (P. putida pyrC’ gene) in E. coli TB2 
 In contrast to the first transformation, here  the mutant pyrB was used, which 
has11 amino acids deleted at the N-terminus. When the E.coli TB2 strain was 
transformed with both plasmids (pKPB-11 and pDBPC’), the strain grew in the absence 
of uracil. As above, the transformants were plated on LB agar containing ampicillin and 
kanamycin. Then, the transformants were again grown in E. coli minimal medium with 
glucose as a carbon source and supplemented with arginine. These transformants grew in 
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the absence of uracil. Thus, the plasmids encoded an active ATCase that complemented 
the pyrB mutant. This ATCase was then purified and used for further study. 
Purification of P. putida ATCase from Wild Type and  
the 11aa Deletion Mutant 
 Both the wild type and the mutant ATCases were purified from E. coli TB2. The 
cells were collected and resuspended in breacking buffer. This cell suspention was passed 
twice through a French press at 1260 pounds per square inch. after breaking the cells, 
30% and 50% ammonium sulfate cuts were done. After 50% cut, the pellet was 
resuspended in ATCase buffer and dialyzed overnight. Then ATCases were purified 
using a phenyl sepharose hydrophobic interaction column (HIC) following ammonium 
sulphate precipitation and the protein were eluted with a predetermined salt 
concentration. When ATCase wild type was purified, SDS- polyacrylamide gel 
electrophoresis was run to show the purity of the enzyme. Results (Fig 13) showed that 
ATCase was partially pure.  
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1                                 2                3               4 
   
Figure 13.  12% SDS denaturing polyacrylamide gel and coomassie stained -11 a
putida ATCase (lane 1), wild type P. putida ATCase (lane 2), E. coli (lane 3), an
marker (lane 4). 
  Native gel electrophoresis was run to estimate the size of the enzyme. The
from this gel are shown in Fig 14. The wild type ATCase has a molecular mass o
484kDa. The mutant ATCase also showed a molecular mass of 484kDa. 
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Figure 14.  10% non-denaturing gel stained for ATCase activity. (1 - E. coli ATCase;      
2 - P. putida wild type ATCase; 3 - P. putida mutant; 4, 5, 6 - same order but exposed to 
42oC; 7 - P. putida wild type exposed to 65oC; 8 - P. putida mutant ATCase exposed to 
65oC. 
Similarly, when the ATCase mutant was purified, it was run in SDS-
polyacrylamide gel electrophoresis and in native gel electrophoresis to show both the 
purity and the size of the enzyme. However, the results indicated that the ATCase mutant 
type was also partially pure and these results are shown in Fig 13. From this figure, the 
two polypeptides with molecular masses of 36 kDa (PyrB) and 44 kDa (PyrC’) were seen 
in both the wild type and the mutant type. The results from the native gel are shown in 
Fig 14. This figure showed that the active dodecamer was assembled in both the wild 
type and the mutant.  
ATCase Assay 
 ATCase assay was performed on the partially purified ATCase from the deletion 
mutant and on the partially purified wild type ATCase. Kinetic studies were then 
performed. The following nucleotides were used to show effector response: ATP, CTP, 
and UTP at final concentrations of 2mM for each.  
 31
 Aspartate saturation curves and carbamoylphosphate saturation curves were 
determined for both the deletion mutant ATCase and for the wild type ATCase. For the 
wild type, the aspartate saturation curves are shown in Fig 15. From this figure, it is clear 
that the specific activity is decreased when the nucleotides (ATP, CTP, and UTP) were 
added with ATP being the most effective. These results indicate that all nucleotides 
inhibit the activity of the enzyme.    
Figure 15.  Aspartate saturation curves of partially purified wild type ATCase from P. 
putida expressed in E. coli TB2.  At concentration of 5mM of aspartate, ARP shows 98% 
inhibition, UTP 64% and CTP 64%. 
 Carbamoylphosphate saturation curves are shown in Fig 16. From this figure, it is 
clear that the nucleotide ATP does not inhibit the wild type ATCase but both UTP and 
CTP activate the enzyme. This suggests that ATP does not act as an inhibitor of 
carbamoylphosphate binding, while an increase in specific activity was observed when 
































activate the enzyme. The final concentration of aspartate in this carbamoylphosphate 
saturation curve was 20mM. However, when the final concentration of the aspartate was 
held constant at 1.5mM, which is the Km for aspartate, the curves suggested that all of the 
nucleotides (ATP, CTP, and UTP) inhibited the activity of the enzyme more than 90% 
(Fig 17). 
 
Figure 16.  Carbamoylphosphate saturation curves of partially purified wild type ATCase 
from P. putida expressed in E. coli TB2.  Carbamoylphosphate concentration was varied 



































Figure 17.  Carbamoylphosphate saturation curves of partially purified wild type ATCase 
from P. putida expressed in E. coli TB2.  Carbamoylphosphate concentration was varied 
while aspartate concentration was held constant at 1.5mM, the Km for aspartate. All of the 
effectors show an inhibition more than 90% in this case. 
 The same assay was done on the purified deletion mutant ATCase. In kinetic 
studies the same effector molecules were used (ATP, CTP, and UTP). Aspartate 
saturation curves for this mutant type are shown in Fig 18. Results from these assays 
indicated that CTP showed no effect on the enzyme activity until 20mM aspartate 
reached which seems to indicate substrate inhibition. Whereas, ATP and UTP inhibited 
the activity of the enzyme, which indicated that the binding site for CTP had been deleted 



























































Figure 18.  Aspartate saturation curves of partially purified mutant ATCase from P. 
putida expressed in E. coli TB2.  Aspartate concentration was varied while 
carbamoylphosphate was held constant at 5mM AT [Asp] Km, ATP shows 40% 
inhibition, UTP 70%,and CTP 10%. 
Carbamoylphosphate saturation curves determined for the mutant ATCase are 
shown in Fig 19. In these curves CTP showed little or no effect on the enzyme activity, 











































Figure 19.  Carbamoylphosphate saturation curves of partially purified mutant ATCase 
from P. putida expressed in E. coli TB2.  Carbamoylphosphate concentration was varied 
while aspartate was held constant at 20mM.  At 1mM of [CP], ATP shows 83%, UTP 





Pseudomonas ATCases, which represent class A enzymes, have been the subject 
of numerous studies (8, 15, 32, 40). ATCases from a number of Pseudomonas species 
have been purified and characterized (1, 14, 30, 32). Class A ATCase is more widely 
distributed in the bacterial world than is the E. coli ATCase. The P. putida ATCase, the 
subject of this study, has an amino terminal carbamoylphosphate-binding domain like the 
E. coli ATCase and a carboxy- terminal aspartate domain.. ATCase in E. coli is active 
only after assembly into a trimer since the active site is formed from two discrete 
polypeptides half-sites (30). These are therefore three active sites per trimer.   
 Sequence analysis of the cloned P. putida ATCase genes showed that ATCase 
was expressed from two ORFs that overlap by 4bp. The first ORF is pyrB, which encodes 
a 36.4kDa polypeptide. The second ORF is a pyrC’, which encodes a 44.2-kDa 
polypeptide (33). The pyrC’ gene product is needed for the ATCase activity, and it has 
been shown that the active pyrC gene product from elsewhere in the chromosome could 
not substitute for the function of the pyrC’ gene product (33). 
E. coli TB2 strain, which is devoid of ATCase activity due to deletion of the 
pyrBI region, was transformed with a plasmid carrying the P. putida pyrB gene and 
another plasmid carrying the pyrC’ gene. This transformation results in the assembly of 
the dodecameric holoenzyme. However, if extracts containing the expressed PyrB 
polypeptides were mixed in vitro with extracts containing the expressed PyrC’ 
polypeptides, an active dodecamer was not assembled (30). On the other hand, an active 
dodecamer was only made if the mixed extracts were denatured completely and then 
allowed to renature slowly (30). In contrast, the E. coli PyrB- and PyrI containing 
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extracts could be merely mixed and an active holoenzyme  assembled without any 
treatment. However, this would suggest that the Pseudomonas enzyme is assembled 
differently from the E. coli enzyme When E. coli TB2 strain was transformed with a 
plasmid carrying –11 aa pyrB gene and another plasmid carrying pyrC’ gene, an active 
ATCase was assembled and this ATCase represents the mutant type in this study.  
In a separate study, it has been shown that Pseudomonas ATCase has a functional 
nucleotide effector binding site which resides at the N-terminus (within the first 60 amino 
acids) of the PyrB catalytic polypeptide (33). In the present work, kinetic studies have 
been done on both the wild type ATCase and the mutant ATCase. The changes made at 
the N-terminal region of the PyrB polypeptide, namely deletion of the first 11 amino 
acids, caused a number of changes in kinetic responses of this mutant ATCase. However, 
the deletion of these amino acids at the N-terminal region of PyrB polypeptide did not 
prevent the truncated polypeptide from assembling into  an active dodecamer. 
Velocity-substrate plots for the wild type ATCase, varying either aspartate or 
carbamoylphosphate, gave Michaelis-Menten kinetics. In the aspartate saturation curve 
(Fig 15), it has been shown that all of the effector nucleotides (ATP, CTP, and UTP) 
inhibited the activity of the enzyme. A significant decrease (98% at 5mM of aspartate) in 
the specific activity of ATCase was observed when ATP was used as an effector 
molecule. Therefore, the enzyme is sensitive to ATP inhibition. In  carbamoylphosphate 
saturation curves (Fig 16) with 20mM final concentration of aspartate, it was clear that 
CTP and UTP activated the enzyme. In other words, an increase in the specific activity 
was observed when CTP and UTP were used as effector molecules. On the other hand, 
ATP showed no effect on the enzyme activity. But when the final concentration of 
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aspartate was set at 1.5mM, the Km all of the effector molecules inhibited the enzyme 
(Fig17). Saturated aspartate therefore alters effector binding capacity. 
Parallel, kinetic studies were carried out the mutant ATCase. Velocity-substrate 
plots, varying either aspartate concentrations or carbamoylphosphate concentrations, also 
gave  Michaelis-Menten kinetics. But due to the deletion of the 11 amino acids at the N-
terminus of PyrB polypeptide the mutant response to effectors was altered. In aspartate 
saturation curves (Fig 18), the mutant ATCase was inhibited by ATP and UTP with CTP 
having no effect at all on the activity of the enzyme until 20 mM of aspartate 
concentration reached. This would suggest that the binding site for CTP has been 
modified due to the deletion of the first 11 amino acids at the N-terminus. When a 
different concentration of carbamoylphosphate was used in carbamoylphosphate 
saturation (Fig 19) curves, the same results were observed from these curves in which 
ATP and UTP inhibited the activity of the enzyme, while CTP showed no effect on the 
enzyme activity. As a results, from both saturation curves (aspartate and 
carbamoylphosphate) it can be said that the CTP binding site has been altered in the 
mutant ATCase. This deletion of the 11 amino acids at the N-terminus caused a change in 
the kinetic responses of this mutant ATCase but it did not prevent the assembly of an 
active dodecamer. 
Purified ATCase from both P. putida wild type and mutant type had an apparent 
molecular mass of 484 kDa as shown by nondenaturing gel electrophoresis that was 
stained for ATCase activity. Thus, the wild type and the mutant  assembled into active 
dodecamers. Wild-type ATCase and the mutant ATCase were exposed to 42°C and 62°C 
to see if heat stability were effected in the mutant. However, results showed no 
 39
significant difference between wild type and mutant. The mutant appears as one band 
suggesting no breakdown products (Fig 14).   
SDS-polyacrylamide gel electrophoresis was run on the P. putida wild type and 
on the mutant ATCase (Fig 13). The two polypeptides with molecular mass of 36 kDa 
that assembled from pyrB and 44 kDa that assembled from pyrC’ were seen in this gel 
(Fig 13). 
In conclusion, this study concerned the effector response of the ATCase from a 
wild type P. putida and from a mutant ATCase with 11 amino acids deleted at the N-
terminus of PyrB polypeptide. Results from this study show that wild-type ATCase was 
more than 90% inhibited by ATP, CTP and UTP at physiological concentrations of 
carbamoylphosphate and aspartate. The truncated mutant ATCase was shown to be 
inhibited by ATP 83% and UTP 58% with no effect by CTP at the physiological 
concentration of each. Thus, the deletion of the first 11 amino acids at the N-terminus 
significantly altered the binding of effectors. The N-terminus is therefore important in the 
allosteric regulation of P. putida ATCase. These results are in accordance with those of 
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